Dasatinib Medications

Dasatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sprycel

Dasatinib

$144.50 per bottle

50mg

Select pack

Dasatinib Compound Information

Dasatinib is a potent oral tyrosine-kinase inhibitor primarily prescribed for chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL). Belonging to the second-generation BCR-ABL inhibitors, it also blocks a range of SRC family kinases, expanding its therapeutic reach beyond imatinib-responsive disease. Approved by the U.S. Food and Drug Administration in 2006 and subsequently by the Therapeutic Goods Administration in Australia, dasatinib is marketed globally under the brand name Sprycel while generic versions are widely available. The drug’s rapid absorption translates into measurable blood levels within hours, and clinical trials have shown durable hematologic and cytogenetic responses that improve long-term survival. Off-label investigations suggest activity in certain solid tumours and myeloproliferative disorders, though such uses lack formal regulatory endorsement. Understanding dasatinib’s pharmacology, dosing options, and safety profile equips patients and caregivers to make informed choices when seeking to buy dasatinib online.

What is Dasatinib?

Dasatinib belongs to the class of second-generation tyrosine-kinase inhibitors (TKIs). The Therapeutic Goods Administration (TGA) granted its first approval in 2008 for CML after the FDA’s 2006 clearance, and later extended the indication to Ph⁺ ALL. The molecule binds competitively to the ATP-binding site of BCR-ABL and SRC kinases, halting phosphorylation cascades that drive malignant cell proliferation. By inhibiting multiple kinases, dasatinib overcomes several imatinib-resistant mutations, making it a valuable option for patients with advanced disease. In Australia, the drug is supplied as Sprycel tablets and as generic dasatinib through our online pharmacy, offering a cost-effective alternative for eligible adults.

How Dasatinib Works

Mechanism of Action

Dasatinib blocks the BCR-ABL fusion protein, a constitutively active tyrosine kinase that results from the t(9;22) translocation. It also inhibits SRC family kinases (SRC, LCK, YES), c-KIT, EPHA2, and PDGFRβ. This broad inhibition disrupts downstream signaling pathways such as MAPK, PI3K-AKT, and STAT, leading to reduced cell survival and proliferation.

Therapeutic Effects

Through dual BCR-ABL and SRC inhibition, dasatinib induces apoptosis of leukemic blasts and restores normal hematopoiesis. Clinical trials demonstrate that patients achieve complete cytogenetic response (CCyR) faster than with first-generation TKIs, translating into lower progression rates.

Onset and Duration

Peak plasma concentrations occur 1-3 hours after oral dosing, with a half-life of roughly 3-5 hours. Despite the relatively short half-life, steady-state inhibition is maintained with once-daily dosing because dasatinib binds tightly to its targets. Studies published in The New England Journal of Medicine reported median times to major molecular response of 3 months for CML patients receiving dasatinib.

Approved Uses and Applications

Approved Indications

Chronic Myeloid Leukemia (chronic phase) - first-line therapy for adult patients; supported by FDA and TGA labeling.
Chronic Myeloid Leukemia (accelerated or blast phase) - used when resistance or intolerance to imatinib occurs.
Philadelphia-chromosome-positive Acute Lymphoblastic Leukemia - administered in combination with chemotherapy protocols.

Off-Label Uses

Evidence from phase II trials suggests activity in:

Systemic mastocytosis - where KIT inhibition is relevant.
Certain solid tumours (e.g., metastatic prostate cancer) - showing modest disease stabilization. These applications lack formal approval in Australia, and clinicians must weigh experimental benefit against regulatory status.

Clinical Efficacy

In a pivotal Lancet study of 1,095 CML patients, dasatinib achieved a 77% rate of complete cytogenetic response at 12 months, compared with 65% for imatinib. For Ph⁺ ALL, a Blood journal trial reported a 5-year overall survival of 55% when dasatinib was incorporated into intensive chemotherapy regimens.

Buying Dasatinib from Our Online Pharmacy

Why Choose Our Service

Through our platform, Australian residents can obtain dasatinib without the delays typical of conventional pharmacies. Our pharmacy service prioritizes privacy, competitive pricing, and reliable delivery, ensuring that treatment continuity is never compromised.

Brand Names and Generic Options

Sprycel (brand tablet, 100 mg) - widely recognized, priced at a premium.
Generic Dasatinib - tablet strengths of 50 mg and 100 mg, offering up to 40% cost savings.
Dasatinib-SR (extended-release formulation) - available for patients requiring flexible dosing schedules.

Quality & Safety

We partner with licensed international pharmacies that meet WHO Good Manufacturing Practice standards, guaranteeing product authenticity and potency.

Pricing & Access

Standard generic dasatinib tablets start at AU$12 per 50 mg tablet, with a lifetime 10% discount on all reorders. Bulk purchase options further reduce per-tablet cost, making long-term therapy financially sustainable.

Discreet Delivery

Express shipping arrives within approximately 7 days, while standard delivery takes up to three weeks. Every package is sealed in anonymous, tamper-evident packaging to protect your privacy.

Dosing, Formulations & Administration

Available Formulations

Dasatinib is supplied as film-coated tablets in 50 mg and 100 mg strengths. No liquid or injectable forms are commercially marketed for adult use.

Typical Dosing Ranges

CML (chronic phase) - clinicians often start at 100 mg once daily; dose adjustments may follow based on tolerance and response.
CML (accelerated/blast phase) - an initial dose of 140 mg once daily is common, with reductions to 100 mg if adverse effects emerge.
Ph⁺ ALL - dosing aligns with the CML protocol, frequently 80-100 mg daily in combination chemotherapy cycles.

These examples illustrate typical practice; a qualified healthcare provider must determine the exact regimen for each individual.

Administration Guidelines

Dasatinib should be taken with a full glass of water, preferably on an empty stomach (at least 30 minutes before or 2 hours after meals) to maximize absorption. Grapefruit juice can increase plasma concentrations and should be avoided. Patients with hepatic or renal impairment may require dose modifications, as outlined in the prescribing information.

Safety Profile & Considerations

Common Side Effects

Myelosuppression (neutropenia, thrombocytopenia) - reported in >30% of patients.
Fluid retention (pleural effusion) - observed in about 15% of cases.
Gastrointestinal upset (nausea, diarrhea) - occurs in roughly 10-20% of users.
Fatigue - noted in 12% of trial participants.

Serious Adverse Events

Severe hemorrhage - rare but requires immediate medical attention.
Cardiac events (QT prolongation, arrhythmia) - monitor ECG in high-risk patients.
Pulmonary arterial hypertension - extremely uncommon; discontinue if identified.

Contraindications

Known hypersensitivity to dasatinib or any tablet excipients.
Severe uncontrolled infection.
Concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin) that could raise dasatinib levels dramatically.

Drug Interactions

CYP3A4 inhibitors/inducers - ketoconazole, rifampicin, and certain antiretrovirals alter exposure.
Anticoagulants - warfarin may require dose adjustment due to increased bleeding risk.
Other TKIs - concurrent administration is contraindicated.

Special Populations

Pregnancy & Breastfeeding - animal studies show teratogenic potential; dasatinib is contraindicated and should be avoided.
Elderly - increased susceptibility to myelosuppression; start at lower doses if frailty is evident.
Renal/Hepatic impairment - dose reduction recommended in moderate to severe dysfunction.

Frequently Asked Questions

How does Dasatinib differ from Imatinib? Dasatinib binds both BCR-ABL and SRC kinases with higher affinity, achieving faster and deeper molecular responses, especially in imatinib-resistant disease.
How long before Dasatinib produces noticeable effects for CML? Hematologic responses often appear within 2-4 weeks, while major cytogenetic remission typically emerges by 3 months of therapy.
What should I do if I experience mild nausea from Dasatinib? Taking the tablet with water on an empty stomach may reduce nausea; if symptoms persist, contact a healthcare provider for possible anti-emetic support.
Can I take Dasatinib with food? High-fat meals reduce absorption; it is best to ingest the medication at least 30 minutes before or 2 hours after meals.
Is it safe to combine Dasatinib with over-the-counter supplements? Some supplements, especially St. John’s Wort (a CYP3A4 inducer), can lower dasatinib levels. Discuss any non-prescribed products with a clinician.
What are the signs of a serious side effect that require urgent care? Unexplained bruising or bleeding, sudden shortness of breath, chest pain, or severe fatigue warrant immediate medical evaluation.
Does Dasatinib affect liver function tests? Transient elevations in liver enzymes occur in a minority of patients; routine monitoring is part of standard therapy protocols.
How should dosing be adjusted for patients with kidney disease? For moderate renal impairment, clinicians often reduce the dose by 50 mg; severe impairment may necessitate further reduction or alternative therapy.
What dietary restrictions apply while on Dasatinib? Avoid grapefruit and grapefruit juice, as they can increase drug exposure and risk of toxicity.
What information should I provide my doctor when discussing Dasatinib?
- Complete list of current medications, including over-the-counter drugs and supplements.
- History of liver, kidney, or cardiac disease.
- Any prior adverse reactions to TKIs.
- Treatment goals and concerns about side effects.

Disclaimer

The information provided about Dasatinib is for general knowledge only. It does not replace professional medical consultation or the official prescribing information for medications containing this ingredient. All treatment decisions, including dosing, formulation selection, and monitoring, should be made under the supervision of a qualified healthcare provider who can assess individual medical history, current medications, and specific health needs. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to medications containing Dasatinib for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication containing Dasatinib.